Heron Group

Heron Therapeutics initiates phase II trial of HTX-011 for post-operative pain

Wednesday, June 17, 2015

Heron Therapeutics has initiated a phase II clinical trial of HTX-011, the company’s lead product candidate for the prevention of post-operative pain, following clearance from the FDA of its IND application for HTX-011. HTX-011, which utilizes Heron’s proprietary Biochronomer drug delivery technology, is a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam.

[Read More]